Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a rare long-duration compounder because it is the rare equity whose credit quality, dividend record, and demand profile collectively rival a sovereign bond while still compounding capital. Healthcare is the one expense Americans cannot defer, and Johnson & Johnson sits at the center of how that spending gets delivered.

Pillar 1: Durability That Outlasts CEOs and Cycles

The post-Kenvue Johnson & Johnson is a focused operator across two engines: Innovative Medicine, which generated $15.43 billion in Q1 2026 (+11.2%), and MedTech at $8.64 billion (+7.7%). Revenue is spread across six priority areas, including Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision, so no single product failure can break the company. Growth drivers like DARZALEX ($3.96 billion, +22.5%), TREMFYA (+68.3%), and CARVYKTI (+62.1%) are doing the heavy lifting while the pipeline (IMAAVY, nipocalimab, OTTAVA robotic surgery) refills the bench. Geographic balance reinforces it: U.S. revenue rose 8.3% while Rest of World rose 11.9%.

This is also one of two U.S. corporations carrying an AAA credit rating from S&P, higher than the U.S. government’s AA+ rating. That balance sheet is the foundation of the “safer than a Treasury bond” argument.

Pillar 2: Income That Compounds Without Drama

The quarterly dividend was raised 3.1% to $1.34 per share, payable June 9, 2026. That marks 64 consecutive years of dividend increases, a record that spans Vietnam, stagflation, the 2008 crisis, and the 2020 pandemic without a single cut. Backing the payout is FY2025 free cash flow of $19.7 billion and net income of $26.8 billion on revenue of $94.19 billion.

For context, the 10-year Treasury yields 4.55% and that coupon never grows. Johnson & Johnson’s payout has risen every year for six decades and is supported by an AAA balance sheet. Income investors get a rising stream from a higher-rated issuer.

Pillar 3: Built to Survive Every Market Cycle

Healthcare demand is non-cyclical. People do not choose when they need cancer therapy, heart valves, or surgical robots. That insulation showed up in Q1 2026 revenue of $24.06 billion (+9.9% YoY), beating the $23.61 billion estimate, with adjusted EPS of $2.70 marking a fourth consecutive beat. Management responded by raising full-year guidance to revenue of $100.3 billion to $101.3 billion and adjusted EPS of $11.45 to $11.65. CEO Joaquin Duato told investors the company is “delivering on its promise for a year of accelerated growth and impact.”

The One Scenario Where It Underperforms

In a roaring bull market led by speculative tech, Johnson & Johnson will lag. It will also continue absorbing the STELARA biosimilar erosion that pulled that drug down 59.7% to $656 million in the quarter. Both factors are already priced into the forever thesis: the patent cliff is in the numbers, and TREMFYA, CARVYKTI, and the ICOTYDE launch are more than offsetting it. Retirement capital is built by surviving every cycle.

The case rests on durability, not timing.